Webinar Recorded on June 24, 2021
Sponsored by Grail
"Cancer remains one of humanity's most intractable diseases, and is expected to surpass heart disease as the leading annual cause of American fatalities by 2030." Utilization of guideline-recommended cancer screening paradigms allows for timely initiation of therapy and superior clinical outcomes for many patients. However, only four screening methodologies are guideline-recommended, and patient adherence to regular screening is suboptimal. Cancers responsible for 71% of cancer deaths have no recommended screening methodologies.
Technical advances in next-generation sequencing and machine learning algorithms have transformed our ability to detect cancer-derived cell-free DNA in the blood. Utilization of minimally-invasive blood-based assays that can detect and localize multiple cancers have the potential to dramatically improve the efficiency of cancer detection. This activity provided an overview of trial data related to the development of a blood-based multi-cancer early detection test.
Speaker: Brenda Wood, PharmD
This webinar is sponsored, developed and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.
Sponsored by:
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
